News J&J settles Ohio lawsuits for $20m as opioid litigation trai... Johnson & Johnson has managed to put opioid litigation in Ohio behind it with a $20 million settlement, saying that will
News FDA approves J&J's prostate cancer drug Erleada in new use, ... The FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has spread.
News Janssen's MS pill outshines Sanofi's Aubagio in phase 3 tria... Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
